- Home
- YQ vs COCP Comparison
YQ vs COCP Comparison
Compare YQ & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- COCP
- Stock Information
- Founded
- YQ 2012
- COCP 2006
- Country
- YQ China
- COCP United States
- Employees
- YQ N/A
- COCP N/A
- Industry
- YQ Other Consumer Services
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- COCP Health Care
- Exchange
- YQ Nasdaq
- COCP Nasdaq
- Market Cap
- YQ 19.4M
- COCP 15.7M
- IPO Year
- YQ 2020
- COCP N/A
- Fundamental
- Price
- YQ $2.23
- COCP $1.80
- Analyst Decision
- YQ
- COCP Strong Buy
- Analyst Count
- YQ 0
- COCP 1
- Target Price
- YQ N/A
- COCP $6.00
- AVG Volume (30 Days)
- YQ 56.7K
- COCP 21.6K
- Earning Date
- YQ 09-03-2025
- COCP 08-13-2025
- Dividend Yield
- YQ N/A
- COCP N/A
- EPS Growth
- YQ N/A
- COCP N/A
- EPS
- YQ N/A
- COCP N/A
- Revenue
- YQ $25,546,613.00
- COCP N/A
- Revenue This Year
- YQ N/A
- COCP N/A
- Revenue Next Year
- YQ N/A
- COCP N/A
- P/E Ratio
- YQ N/A
- COCP N/A
- Revenue Growth
- YQ N/A
- COCP N/A
- 52 Week Low
- YQ $1.26
- COCP $1.12
- 52 Week High
- YQ $3.19
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- YQ 57.45
- COCP 69.71
- Support Level
- YQ $2.15
- COCP $1.46
- Resistance Level
- YQ $2.39
- COCP $1.60
- Average True Range (ATR)
- YQ 0.16
- COCP 0.08
- MACD
- YQ 0.00
- COCP 0.02
- Stochastic Oscillator
- YQ 54.29
- COCP 92.31
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).